159 related articles for article (PubMed ID: 28447382)
1. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
[TBL] [Abstract][Full Text] [Related]
2. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
[TBL] [Abstract][Full Text] [Related]
3. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
4. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
5. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
7. Vitamin C promotes anti-leukemia of DZNep in acute myeloid leukemia.
Long B; Shan Y; Sun Y; Wang T; Li X; Huang K; Zhang W; He Y; Wen R; Li Y; Mai Y; Feng Y; Zhang T; Kang B; Zhang C; Zhu Y; Gu J; Liu J; Zhang X; Pan G
Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166357. PubMed ID: 35143932
[TBL] [Abstract][Full Text] [Related]
8. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
[TBL] [Abstract][Full Text] [Related]
9. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia.
Wang J; He N; Wang R; Tian T; Han F; Zhong C; Zhang C; Hua M; Ji C; Ma D
Sci Rep; 2020 Feb; 10(1):2706. PubMed ID: 32066746
[TBL] [Abstract][Full Text] [Related]
10. Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML).
Jiang X; Lim CZ; Li Z; Lee PL; Yatim SM; Guan P; Li J; Zhou J; Pan J; Chng WJ; Chai CL; Yu Q
PLoS One; 2015; 10(4):e0122983. PubMed ID: 25928216
[TBL] [Abstract][Full Text] [Related]
11. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.
Ueda K; Yoshimi A; Kagoya Y; Nishikawa S; Marquez VE; Nakagawa M; Kurokawa M
Cancer Sci; 2014 May; 105(5):512-9. PubMed ID: 24612037
[TBL] [Abstract][Full Text] [Related]
13. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
[TBL] [Abstract][Full Text] [Related]
14. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
15. Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia.
Yang C; Gu Y; Ge Z; Song C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232694
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
[TBL] [Abstract][Full Text] [Related]
17. HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.
He Z; Zhang S; Ma D; Fang Q; Yang L; Shen S; Chen Y; Ren L; Wang J
J Transl Med; 2019 Nov; 17(1):366. PubMed ID: 31711520
[TBL] [Abstract][Full Text] [Related]
18. The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.
Aury-Landas J; Girard N; Lhuissier E; Adouane D; Delépée R; Boumediene K; Baugé C
Cell Physiol Biochem; 2019; 53(4):731-745. PubMed ID: 31613064
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
Fujita S; Honma D; Adachi N; Araki K; Takamatsu E; Katsumoto T; Yamagata K; Akashi K; Aoyama K; Iwama A; Kitabayashi I
Leukemia; 2018 Apr; 32(4):855-864. PubMed ID: 28951561
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
